Language: Dutch  |  Français

Gilead Sciences Belgium BVBA/SPRL

Park Lane
Culliganlaan 2D
1831 Diegem
Belgium

Phone: 32 24 01 35 50
Fax: 32 24 01 35 51

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.

Located in Diegem, outside of Brussels, Gilead’s Belgium office provides medical, sales and marketing support of our products for Belgium and Luxembourg.

Transparency Reporting
In line with local Transparency Reporting requirements, Gilead is disclosing its interactions with HealthCare Professionals and HealthCare Organisations in Luxembourg in the following report, supported by a Methodological Note. Enquiries about the report should be directed to: http://www.gilead.com/news/media-inquiries.

Gilead Sciences Luxembourg EFPIA Report 2016 (in English)
Gilead Sciences Luxembourg EFPIA Methodological Note 2016
Gilead Sciences Luxembourg EFPIA Report 2015 (in English)
Gilead Sciences Luxembourg EFPIA Methodological Note 2015

To make research and development costs as transparent as possible, EFPIA (European Federation of Pharmaceutical Industries and Associations) asked all member pharmaceutical companies to publish their research and development costs on their own websites (click here for "Disclosure Codes make the cost of research and development as transparent as possible: EFPIA has asked all affiliated drug manufacturers in Europe to publish these amounts on their company website in 2016” (click here for the EFPIA Disclosure Code). The research and development costs include spend on non-clinical studies, clinical trials and prospective non-intervention studies. These costs are published annually in aggregate by each member company at a national level.

Member drugs development companies paid in 2016 is € 982.650,58


Gilead provided support for the following patient organisations in 2016 via sponsorship agreements or unrestricted educational grants. For a listing of previous years' grants, click here.

Belgium

  • Grant Recipient
    Description of Activity
    Amount Funded €
  • CHAC

    Support 2016 in ‘battle against hepatitis’

    12000
  • Sensoa
    Hepatitis C information to MSM
    1,500
  • Sidasol
    Testing Week
    2,800
  • Namur Entraide Sida
    Support service for co-infected persons
    5,175
  • Aide Info Sida BXL
    EU Testing Week
    7,550
Language: Dutch  |  Français


This page is intended for visitors outside of the United States.